Table 1.
Clinical and pathological characteristics in nondiabetic and diabetic patients.
| Nondiabetics | Diabetics | Univariate (P) | |
|---|---|---|---|
| Median age (Years) | 48.0 | 52.5 | 0.207 |
| T | |||
| 1 | 27 (12%) | 4 (9%) | 0.684 |
| 2 | 77 (34%) | 12 (29%) | |
| 3 | 54 (24%) | 14 (35%) | |
| 4 | 67 (30%) | 10 (27%) | |
|
| |||
| N | |||
| 0 | 41 (18%) | 9 (23%) | 0.695 |
| 1 | 95 (42%) | 14 (34%) | |
| 2 | 56 (25%) | 8 (20%) | |
| 3 | 33 (15%) | 9 (23%) | |
|
| |||
| Grade | |||
| 1 | 29 (13%) | 7 (18%) | 0.087 |
| 2 | 81 (36%) | 20 (49%) | |
| 3 | 115 (51%) | 13 (33%) | |
|
| |||
| Hormone receptor | |||
| Positive | 112 (49%) | 28 (70%) | 0.018 |
| Negative | 113 (51%) | 12 (30%) | |
|
| |||
| HER2 | |||
| Positive | 60 (27%) | 5 (13%) | 0.079 |
| Negative | 165 (73%) | 35 (87%) | |
|
| |||
| Triple-negative | |||
| Positive | 59 (26%) | 7 (18%) | 0.262 |
| Negative | 166 (74%) | 33 (82%) | |
|
| |||
| Metastatic site | |||
| Single | 122 (54%) | 18 (45%) | 0.306 |
| Multiple | 103 (46%) | 22 (55%) | |
|
| |||
| Type of metastases | |||
| Nonvisceral | 86 (38%) | 16 (40%) | 0.790 |
| Visceral | 139 (62%) | 24 (60%) | |
|
| |||
| Median BMI at recurrence | 26.8 | 27.5 | 0.359 |
T: tumor stage according to TNM; N: nodal stage according to TNM; BMI: body mass index.